Literature DB >> 26422743

Ibrutinib in Refractory Classic Hodgkin's Lymphoma.

Mehdi Hamadani1, Sriram Balasubramanian, Parameswaran N Hari.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26422743     DOI： 10.1056/NEJMc1505857

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?

Authors:  Niloufer Khan; Alison J Moskowitz
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

2.  Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.

Authors:  Anita Kumar; Santosha Vardhana; Alison J Moskowitz; Pierluigi Porcu; Ahmet Dogan; Jason A Dubovsky; Matthew J Matasar; Zhigang Zhang; Anas Younes; Steven M Horwitz
Journal:  Blood Adv       Date:  2018-04-24

3.  Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.

Authors:  Alankrita Taneja; Jade Jones; Stefania Pittaluga; Irina Maric; Mohammed Farooqui; Inhye E Ahn; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-07-06

4.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

Review 5.  Pembrolizumab in classical Hodgkin's lymphoma.

Authors:  Joseph Maly; Lapo Alinari
Journal:  Eur J Haematol       Date:  2016-05-30       Impact factor: 2.997

Review 6.  Syk inhibitors in clinical development for hematological malignancies.

Authors:  Delong Liu; Aleksandra Mamorska-Dyga
Journal:  J Hematol Oncol       Date:  2017-07-28       Impact factor: 17.388

Review 7.  Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.

Authors:  David A Bond; Lapo Alinari
Journal:  J Blood Med       Date:  2017-05-11

Review 8.  Immune Checkpoint Inhibition in Hodgkin Lymphoma.

Authors:  Ryan H Moy; Anas Younes
Journal:  Hemasphere       Date:  2018-02-16

9.  Editing of mouse and human immunoglobulin genes by CRISPR-Cas9 system.

Authors:  Taek-Chin Cheong; Mara Compagno; Roberto Chiarle
Journal:  Nat Commun       Date:  2016-03-09       Impact factor: 14.919

10.  Analysis of the mutational landscape of classic Hodgkin lymphoma identifies disease heterogeneity and potential therapeutic targets.

Authors:  Elena Mata; Antonio Díaz-López; Ana M Martín-Moreno; Margarita Sánchez-Beato; Ignacio Varela; María J Mestre; Carlos Santonja; Fernando Burgos; Javier Menárguez; Mónica Estévez; Mariano Provencio; Beatriz Sánchez-Espiridión; Eva Díaz; Carlos Montalbán; Miguel A Piris; Juan F García
Journal:  Oncotarget       Date:  2017-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.